Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$56.23 USD
-6.04 (-9.70%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $56.85 +0.62 (1.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 161 - 180 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hip Checking the Competition; They Can Take ''5211 Too; Assuming Coverage at Buy, $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Join Us for Our Spring NASH Bash, with 18 NASH Companies and 6 KOLs
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK5211 Data Positive for Hip Fracture Recovery; PT to $5.50
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SARM Hits Primary and Multiple Secondary Endpoints Across All Doses: Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Underappreciated Microcap With Multiple Shots on Goal; Assume Buy, $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E